Chinook Therapeutics KDNY Stock
Chinook Therapeutics Price Chart
Chinook Therapeutics KDNY Financial and Trading Overview
Chinook Therapeutics stock price | 40.39 USD |
Previous Close | 37.63 USD |
Open | 37.7 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1200 |
Day's Range | 37.45 - 37.92 USD |
52 Week Range | 16.55 - 38.14 USD |
Volume | 3.08M USD |
Avg. Volume | 1.2M USD |
Market Cap | 2.53B USD |
Beta (5Y Monthly) | 0.351091 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 40.1 USD |
KDNY Valuation Measures
Enterprise Value | 2.22B USD |
Trailing P/E | N/A |
Forward P/E | -10.95942 |
PEG Ratio (5 yr expected) | -1.3 |
Price/Sales (ttm) | 481.98297 |
Price/Book (mrq) | 6.1260533 |
Enterprise Value/Revenue | 421.558 |
Enterprise Value/EBITDA | -11.252 |
Trading Information
Chinook Therapeutics Stock Price History
Beta (5Y Monthly) | 0.351091 |
52-Week Change | 102.73% |
S&P500 52-Week Change | 20.43% |
52 Week High | 38.14 USD |
52 Week Low | 16.55 USD |
50-Day Moving Average | 23.27 USD |
200-Day Moving Average | 22.79 USD |
KDNY Share Statistics
Avg. Volume (3 month) | 1.2M USD |
Avg. Daily Volume (10-Days) | 3.82M USD |
Shares Outstanding | 67.04M |
Float | 55.92M |
Short Ratio | 4.91 |
% Held by Insiders | 2.61% |
% Held by Institutions | 96.29% |
Shares Short | 4.17M |
Short % of Float | 7.27% |
Short % of Shares Outstanding | 6.23% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -3843.62% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -23.50% |
Return on Equity (ttm) | -51.56% |
Income Statement
Revenue (ttm) | 5.26M USD |
Revenue Per Share (ttm) | 0.08 USD |
Quarterly Revenue Growth (yoy) | -32.20% |
Gross Profit (ttm) | -135083000 USD |
EBITDA | -197027008 USD |
Net Income Avi to Common (ttm) | -216358000 USD |
Diluted EPS (ttm) | -3.21 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 350.38M USD |
Total Cash Per Share (mrq) | 5.24 USD |
Total Debt (mrq) | 38.26M USD |
Total Debt/Equity (mrq) | 9.28 USD |
Current Ratio (mrq) | 7.037 |
Book Value Per Share (mrq) | 6.172 |
Cash Flow Statement
Operating Cash Flow (ttm) | -143427008 USD |
Levered Free Cash Flow (ttm) | -84437000 USD |
Profile of Chinook Therapeutics
Country | United States |
State | WA |
City | Seattle |
Address | 400 Fairview Avenue North |
ZIP | 98109 |
Phone | 206 485 7241 |
Website | https://www.chinooktx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 214 |
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Q&A For Chinook Therapeutics Stock
What is a current KDNY stock price?
Chinook Therapeutics KDNY stock price today per share is 40.39 USD.
How to purchase Chinook Therapeutics stock?
You can buy KDNY shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chinook Therapeutics?
The stock symbol or ticker of Chinook Therapeutics is KDNY.
Which industry does the Chinook Therapeutics company belong to?
The Chinook Therapeutics industry is Biotechnology.
How many shares does Chinook Therapeutics have in circulation?
The max supply of Chinook Therapeutics shares is 67.05M.
What is Chinook Therapeutics Price to Earnings Ratio (PE Ratio)?
Chinook Therapeutics PE Ratio is 0.00000000 now.
What was Chinook Therapeutics earnings per share over the trailing 12 months (TTM)?
Chinook Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Chinook Therapeutics company belong to?
The Chinook Therapeutics sector is Healthcare.
Chinook Therapeutics KDNY included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16103.45 USD — |
+0.82
|
4.52B USD — | 16094.17 USD — | 16247.59 USD — | — - | 4.52B USD — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2078.81 USD — |
-0.4
|
— — | 2075.76 USD — | 2093.28 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2568.29 USD — |
+0.16
|
— — | 2566.7 USD — | 2581.47 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4337.34 USD — |
-0.65
|
— — | 4335.84 USD — | 4376.86 USD — | — - | — — |
NASDAQ HealthCare IXHC | 986.88 USD — |
-0.25
|
— — | 986.44 USD — | 994.67 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7837.41 USD — |
+0.85
|
— — | 7832.7 USD — | 7908.95 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}